fah hospital policy blog

Perspectives on health policy affecting America’s hospitals and the patients we serve.

Category Archives: pharmaceuticals

FAH Comments on 2019 OPPS Proposed Rule

September 24, 2018 | FAH Policy Blog Team

Category: Financing, Pharmaceuticals, Quality

This afternoon FAH filed comments with CMS regarding the 2019 Hospital Outpatient Prospective Payment System (OPPS) proposed rule.

Read More »

FAH Comments on Senators Grassley and Durbin Drug Pricing Amendment

August 21, 2018 | FAH Policy Blog Team

Category: FAH News, Legislation, Pharmaceuticals

Rising and excessive drug prices threaten patient access to the drugs they need and can undermine the care physicians see as necessary for patients. The Grassley-Durbin amendment (#3787) would take a great leap forward in providing consumers useful information on drug prices that could help them buy smart. And, the public display of prices could put a spotlight on those high prices and bring them down.

Read More »

FAH Comments on HHS Blueprint to Lower Drug Prices

July 17, 2018 | FAH Policy Blog Team

Category: Pharmaceuticals, Transparency

The Federation of American Hospitals (FAH) sent a letter Monday to HHS Secretary Alex Azar commenting on the agency’s recently released Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

Read More »

FAH, 45 Other Groups Urge Senators to Pass CREATES Act

June 07, 2018 | FAH Policy Blog Team

Category: FAH News, Legislation, Medicare, Pharmaceuticals

A wide ranging coalition of 46 groups, that include FAH, from across the health care spectrum sent a letter today to leaders of the Senate Judiciary Committee urging swift action on the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974).

Read More »